Results of a 12-week open-label, non-interventional study of the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic

The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic anti-inflammatory drugs (DMARDs) and biological DMARDs on the course and outcomes o...

Full description

Bibliographic Details

Published in:	Научно-практическая ревматология
Main Authors:	A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2023-03-01
Subjects:	rheumatoid arthritis covid-19 olokizumab rituximab
Online Access:	https://rsp.mediar-press.net/rsp/article/view/3274